scholarly article | Q13442814 |
P2093 | author name string | Liesbeth Hameetman | |
Anne-Marie Cleton-Jansen | |||
Pancras C W Hogendoorn | |||
Judith V M G Bovée | |||
Anthonie H M Taminiau | |||
Leida B Rozeman | |||
P2860 | cites work | Bcl-2 lies downstream of parathyroid hormone-related peptide in a signaling pathway that regulates chondrocyte maturation during skeletal development | Q24315654 |
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes | Q24534395 | ||
Vertebrate Hedgehog signalling modulated by induction of a Hedgehog-binding protein | Q28137935 | ||
Chondrosarcoma of the phalanx: a locally aggressive lesion with minimal metastatic potential: a report of 35 cases and a review of the literature. | Q33765771 | ||
A mutant PTH/PTHrP type I receptor in enchondromatosis | Q34521165 | ||
Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C. | Q34552391 | ||
Benign and malignant cartilage tumors of bone and joint: their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. I. The intramedullary cartilage tumors | Q41537181 | ||
Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. | Q43996886 | ||
Transforming growth factor-beta isoform and receptor expression in chondrosarcoma of bone. | Q44001166 | ||
EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast | Q44490794 | ||
Expression of cartilage growth plate signalling molecules in chondroblastoma. | Q44705491 | ||
P433 | issue | 4 | |
P921 | main subject | chondrosarcoma | Q1076087 |
P304 | page(s) | 476-482 | |
P577 | publication date | 2005-03-01 | |
P1433 | published in | Journal of Pathology | Q400296 |
P1476 | title | Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. | |
P478 | volume | 205 |
Q37150809 | Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma |
Q38312291 | Array-comparative genomic hybridization of central chondrosarcoma: identification of ribosomal protein S6 and cyclin-dependent kinase 4 as candidate target genes for genomic aberrations. |
Q34454218 | BMP and TGFbeta pathways in human central chondrosarcoma: enhanced endoglin and Smad 1 signaling in high grade tumors |
Q58705635 | Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma |
Q37740672 | Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma |
Q42542315 | CORR Insights®: Is Needle Biopsy Clinically Useful in Preoperative Grading of Central Chondrosarcoma of the Pelvis and Long Bones? |
Q37763842 | Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. |
Q35832096 | Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix |
Q35841926 | Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro |
Q34591289 | Chondrosarcoma: with updates on molecular genetics |
Q35070800 | Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation |
Q84522319 | Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes |
Q37281697 | Destabilization of the IFT-B cilia core complex due to mutations in IFT81 causes a Spectrum of Short-Rib Polydactyly Syndrome |
Q53574637 | Differential expression of runx2 and Indian hedgehog in cartilaginous tumors. |
Q36212898 | Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment |
Q38434804 | Exploring the key genes and pathways in enchondromas using a gene expression microarray |
Q35668685 | FGFR3 Deficiency Causes Multiple Chondroma-like Lesions by Upregulating Hedgehog Signaling |
Q53070824 | Genetic alterations in chondrosarcomas - keys to targeted therapies? |
Q41259136 | Identification of novel biomarker candidates for immunohistochemical diagnosis to distinguish low-grade chondrosarcoma from enchondroma |
Q36676500 | Loss of β-catenin induces multifocal periosteal chondroma-like masses in mice |
Q38588243 | Molecular basis of differentiation therapy for soft tissue sarcomas |
Q36613603 | Molecular pathology of chondroid neoplasms: part 1, benign lesions |
Q36078319 | No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone |
Q37294776 | PTHR1 mutations associated with Ollier disease result in receptor loss of function |
Q41330027 | Patched-one or smoothened gene mutations are infrequent in chondrosarcoma |
Q37457708 | Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. |
Q37185828 | Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells |
Q42677448 | TGF-β signalling and PEG10 are mutually exclusive and inhibitory in chondrosarcoma cells |
Q88167587 | Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation |
Q36392814 | Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist |
Q59196037 | The Role of EXT1 in Nonhereditary Osteochondroma: Identification of Homozygous Deletions |
Q53547784 | The role of noncartilage-specific molecules in differentiation of cartilaginous tumors: lessons from chondroblastoma and chondromyxoid fibroma. |
Search more.